ArticleJournal of public health research2026
Parkinson's disease mortality and years of potential life lost in Iran: A 10-year national analysis (2013-2023).
Article in Journal of public health research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is a leading neurodegenerative disorder associated with increasing global morbidity and premature mortality. Despite its growing burden, national trends in PD-related mortality and years of potential life lost (YPLL) remain understudied in Iran. Objectives: To examine temporal trends in PD-related mortality and YPLL in Iran from 2013 to 2023 and to assess demographic and regional disparities. Methods: This repeated cross-sectional study used data from the Iranian National Death Registration System. All deaths attributed to PD (ICD-10 codes G20 and G21) between 2013 and 2023 were included. Crude age-specific and cause-specific mortality rates were calculated, and YPLL was estimated using standard methods. Temporal trends were assessed using regression-based analyses. Spatial patterns were evaluated using ArcGIS, and statistical analyses were performed in Stata version 17. Results: A total of 9229 PD-related deaths were recorded. Crude mortality rates increased from 0.21 per 100,000 in 2013 to 1.77 in 2023, while YPLL rose from 1.21 to 7.86 per 100,000. Males consistently exhibited higher mortality and YPLL than females. Geospatial analysis identified higher burdens in Tehran, Khorasan Razavi, Isfahan, and Fars. Lower rates in several rural provinces may partly reflect underreporting or disparities in healthcare access. Conclusion: The observed increase in crude PD-related mortality and YPLL over the past decade suggests a growing public health challenge in Iran. However, these trends should be interpreted with caution, as they may be influenced by population aging, improvements in diagnosis, and changes in death registration practices. Strengthening early diagnosis, specialized care, and equitable access to neurological services-particularly in underserved regions-remains a public health priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.